MBX — Microbix Biosystems Income Statement
0.000.00%
Last trade - 00:00- CA$35.58m
- CA$29.88m
- CA$25.39m
- 66
- 73
- 27
- 56
Annual income statement for Microbix Biosystems, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.5 | 18.6 | 19.1 | 16.5 | 25.4 |
| Cost of Revenue | |||||
| Gross Profit | 4.66 | 11 | 11.1 | 7.48 | 15.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 15.2 | 15.4 | 17.2 | 16.6 | 21.7 |
| Operating Profit | -4.66 | 3.23 | 1.87 | -0.039 | 3.67 |
| Net Income Before Taxes | -4.66 | 3.23 | 1.87 | -0.039 | 3.67 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.23 | 3.23 | 1.79 | -0.039 | 3.52 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.23 | 3.23 | 1.79 | -0.039 | 3.52 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.23 | 3.23 | 1.79 | -0.039 | 3.52 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.04 | 0.023 | 0.013 | -0.023 | 0.026 |